Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.63 |
| ▸ | CDK8 | P49336 | 4/20 | 0.63 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | SGK1 | O00141 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15500802 | 0.86 | CDK8 (0.64) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL15500811 | 0.86 | AXL (0.60) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL15500801 | 0.85 | AXL (0.59) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL1801753 | 0.85 | CDK8 (0.59) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL1799235 | 0.84 | PDPK1 (0.56) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL1797818 | 0.83 | PDPK1 (0.57) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL15500786 | 0.83 | PDPK1 (0.57) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL1796715 | 0.82 | AXL (0.61) | AXLCDK8TNIKPDPK1SGK1 | |
| SCHEMBL1799928 | 0.81 | AXL (0.64) | AXLCDK8TNIKSGK1KIT | |
| SCHEMBL15500880 | 0.81 | SGK1 (0.57) | AXLCDK8TNIKSGK1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070086-B1 | AZAINDOLE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-9782392-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9782392-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9782392-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-10 | — | — | US | disclosed |
| CN-105980383-B | Azaindole derivatives | 大鹏药品工业株式会社 | 2017-07-04 | — | — | CN | disclosed |
| US-9676773-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676773-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676773-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170119743-A1 | AZAINDOLE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170119743-A1 | AZAINDOLE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20160340353-A1 | AZAINDOLE DERIVATIVE | TAIHO PHARMARCEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| CN-105980383-A | Azaindole derivatives | 大鹏药品工业株式会社 | 2016-09-28 | — | — | CN | disclosed |
| EP-3070086-A1 | AZAINDOLE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015119126-A1 | AZAINDOLE DERIVATIVE | 大鵬薬品工業株式会社 | 2015-08-13 | — | — | WO | disclosed |
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| EP-2325184-A1 | Azaindoles useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119743-A1 | AZAINDOLE DERIVATIVE | JAK3, JAK1, JAK2 | AXL 3633/4885CDK8 550/4885TNIK 396/4885 |
| US-20160340353-A1 | AZAINDOLE DERIVATIVE | JAK3, JAK1, JAK2 | AXL 1732/4885CDK8 233/4885TNIK 1080/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | AXL 4302/4885CDK8 436/4885TNIK 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.